New Launch22 Sept 2025, 04:08 pm
Alkem Laboratories Launches Affordable Pertuzumab Biosimilar 'Pertuza' in India for HER2-positive Breast Cancer Treatment
AI Summary
Alkem Laboratories Ltd. has announced the launch of Pertuza, a pertuzumab biosimilar, in India for the treatment of HER2-positive breast cancer. The biosimilar, developed by Alkem's biotech subsidiary, has demonstrated equivalence in efficacy, safety, and immunogenicity to the innovator's product in a pivotal phase 3 clinical trial. Alkem aims to expand access to this critical therapy, which has been cost-prohibitive for many patients in India, by offering an affordable option backed by trusted science and a strong oncology distribution network.
Key Highlights
- Alkem Laboratories launches Pertuza, a pertuzumab biosimilar, in India for treatment of HER2-positive breast cancer.
- Pertuza is an affordable, indigenously-developed and manufactured biosimilar of pertuzumab, demonstrating equivalence in efficacy, safety, and immunogenicity in a pivotal phase 3 clinical trial.
- Accessibility of pertuzumab in India has been a challenge due to cost barriers, and Alkem's launch of Pertuza aims to ensure scientific credibility and improved accessibility.
- Alkem has a growing portfolio of oncology drugs, including cetuximab biosimilar, denosumab biosimilar, bevacizumab biosimilar, and romiplostim biosimilar.
- Alkem's commitment to global health improvement is reflected in their mission of 'Inspiring Healthier Lives'.